Ann Driessen

Ann Driessen

Auto-generated profile, based on publicly available information

Ann Driessen


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2017 in JCI Insight
Verified
Journal Article
Open access
PDF file
PLPhilippe Lefebvre
Philippe Lefebvre
FLFanny Lalloyer
Fanny Lalloyer
EBEric Baugé
Eric Baugé
MPMichal Pawlak
Michal Pawlak
CGCéline Gheeraert
Céline Gheeraert
BSBart Staels
Bart Staels
Nonalcoholic fatty liver disease prevalence is soaring with the obesity pandemic, but the pathogenic mechanisms leading to the progression toward active nonalcoholic steatohepatitis (NASH) and fibrosis, major causes of liver-related death, are poorly defined. To identify key components during the progression toward NASH and fibrosis, we investigated the liver transcriptome in a human cohort of NASH patients. The transition from histologically proven fatty liver to NASH and fibrosis was characterized by gene expression patterns that successively reflected altered functions in metabolism, inflammation, and epithelial-mesenchymal transition. A meta-analysis combining our and public human transcriptomic datasets with murine models of NASH and fibrosis defined a molecular signature characterizing NASH and fibrosis and evidencing abnormal inflammation and extracellular matrix (ECM) homeostasis. Dermatopontin expression was found increased in fibrosis, and reversal of fibrosis after gastric bypass correlated with decreased dermatopontin expression. Functional studies in mice identified an active role for dermatopontin in collagen deposition and fibrosis. PPARα activation lowered dermatopontin expression through a transrepressive mechanism affecting the Klf6/TGFβ1 pathway. Liver fibrotic histological damages are thus characterized by the deregulated expression of a restricted set of inflammation- and ECM-related genes. Among them, dermatopontin may be a valuable target to reverse the hepatic fibrotic process.

1 August 2021 in Journal of Hepatology
Verified
Journal Article
Open access
MNMaxime Nachit
Maxime Nachit
WKWilhelmus J. Kwanten
Wilhelmus J. Kwanten
JTJean-Paul Thissen
Jean-Paul Thissen
BBBart Op De Beeck
Bart Op De Beeck
LGLuc Van Gaal
Luc Van Gaal
ILIsabelle A. Leclercq
Isabelle A. Leclercq
To evaluate the association between muscle mass and fatty infiltration and biopsy-assessed NAFLD in patients with obesity. At inclusion (n=184) and 12 months after a dietary intervention (n=15) or a bariatric surgery (n=24), we evaluated NAFLD with liver biopsy, skeletal muscle mass index with computed tomography (CT-SMI) and bioelectrical impedance analysis (BIA-SMI). We developed an index to evaluate absolute fat content in muscle (skeletal muscle fat index; SMFI) from CT-based psoas muscle density (SMFIPsoas). Muscle mass was higher in patients with NAFLD than in those without (CT-SMI 56.8±9.9 vs 47.4±6.5 cm2/m,2 p<0.0001). There was no association between sarcopenia and NASH. SMFIPsoas was higher in NASH ≥F2 and early NASH F0-1 than in NAFL (78.5±23.6 and 73.1±15.6 vs 61.2±12.6, p<0.001). One point in score for any of the individual cardinal NASH features (i.e. steatosis, inflammation or ballooning) associated with an increase in SMFIPsoas (all p<0.05). The association between SMFIPsoas and NASH was highly significant even after adjustment for multiple confounders (all p<0.025). After intervention (n=39), NASH improvement, defined by NAS <3 or 2-point NAS score reduction, was achieved in more than 75% of patients (n=25 or n=27, respectively) that had pre-established NASH at inclusion (n=32) and associated with a significant decrease in SMFIPsoas (p<0.001). Strikingly, all patients who had ≥11% reduction in SMFIPsoas achieved NASH improvement (14/14, p<0.05). Muscle fat content, but not muscle mass, is strongly and independently associated with NASH. All individuals who achieved a ≥11% decrease in SMFIPsoas after intervention improved their NASH. These data call to explore muscle fatty infiltration as a potential marker for (and perhaps a pathophysiological contributor to) NASH. The fat content in skeletal muscles is highly reflective of the severity of non-alcoholic fatty liver disease (NAFLD) in patients with morbid obesity. In particular, muscle fat content is strongly associated with non-alcoholic steatohepatitis (NASH) and decreases upon NASH improvement. These data call to explore muscle fatty infiltration as a potential marker and perhaps a pathophysiological contributor to NASH.

1 June 2020 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
ACAnneline Cremer
Anneline Cremer
PDPieter Demetter
Pieter Demetter
MVMartine De Vos
Martine De Vos
JRJean-François Rahier
Jean-François Rahier
FBFilip Baert
Filip Baert
DFDenis Franchimont
Denis Franchimont

1 December 2017 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
TCT. Chapelle
T. Chapelle
BBB. Op de Beeck
B. Op de Beeck
ADA. Driessen
A. Driessen
GRGeert 11761447140 Roeyen
Geert 11761447140 Roeyen
BBB. Bracke
B. Bracke
SFS. Francque
S. Francque

4 June 2020 in Cancers
Verified
Journal Article
Open access
PDF file
GBGitta Boons
Gitta Boons
TVTimon Vandamme
Timon Vandamme
JIJoe Ibrahim
Joe Ibrahim
GRGeert 11761447140 Roeyen
Geert 11761447140 Roeyen
ADAnn Driessen
Ann Driessen
KBKen Op de Beeck
Ken Op de Beeck
DNA methylation is a crucial epigenetic mechanism for gene expression regulation and cell differentiation. Furthermore, it was found to play a major role in multiple pathological processes, including cancer. In pancreatic neuroendocrine neoplasms (PNENs), epigenetic deregulation is also considered to be of significance, as the most frequently mutated genes have an important function in epigenetic regulation. However, the exact changes in DNA methylation between PNENs and the endocrine cells of the pancreas, their likely cell-of-origin, remain largely unknown. Recently, two subtypes of PNENs have been described which were linked to cell-of-origin and have a different prognosis. A difference in the expression of the transcription factor PDX1 was one of the key molecular differences. In this study, we performed an exploratory genome-wide DNA methylation analysis using Infinium Methylation EPIC arrays (Illumina) on 26 PNENs and pancreatic islets of five healthy donors. In addition, the methylation profile of the PDX1 region was used to perform subtyping in a global cohort of 83 PNEN, 2 healthy alpha cell and 3 healthy beta cell samples. In our exploratory analysis, we identified 26,759 differentially methylated CpGs and 79 differentially methylated regions. The gene set enrichment analysis highlighted several interesting pathways targeted by altered DNA methylation, including MAPK, platelet-related and immune system-related pathways. Using the PDX1 methylation in 83 PNEN, 2 healthy alpha cell and 3 healthy beta cell samples, two subtypes were identified, subtypes A and B, which were similar to alpha and beta cells, respectively. These subtypes had different clinicopathological characteristics, a different pattern of chromosomal alterations and a different prognosis, with subtype A having a significantly worse prognosis compared with subtype B (HR 0.22 [95% CI: 0.051–0.95], p = 0.043). Hence, this study demonstrates that several cancer-related pathways are differently methylated between PNENs and normal islet cells. In addition, we validated the use of the PDX1 methylation status for the subtyping of PNENs and its prognostic importance.

17 March 2020 in Acta Clinica Belgica
Verified
Journal Article
Closed access
LWLaura Wuyts
Laura Wuyts
AJAnnelies Janssens
Annelies Janssens
LVLuisa Vonghia
Luisa Vonghia
PMPeter Michielsen
Peter Michielsen
JRJo Raskin
Jo Raskin
TVThomas Vanwolleghem
Thomas Vanwolleghem
Exhaustion of antigen-specific T-cells in order to escape immune destruction is frequently seen in chronic viral infection and different types of cancer. Blockade of overexpressed negative co-stimulatory pathways, a process known as immune checkpoint modulation, is a promising novel therapy that could improve the treatment of liver diseases with features of T cell exhaustion. We present a case of a 54-year-old hepatitis C virus (HCV) positive patient with an acute flare of hepatitis during nivolumab treatment for a stage IV lung carcinoma, an anti-programmed death-1 (PD-1) immunotherapy. Retrospective testing of HCV RNA documented infection more than 6 months ago. Nivolumab treatment was associated with an alanine aminotransferase (ALT) flare reaching a peak value of 663 U/L, along with bilirubin levels of 0.74 mg/dL and no signs of coagulopathy. The assumption of a nivolumab-associated autoimmune hepatitis led to the interruption of the immune checkpoint inhibitor treatment. However, a subsequent 1-log decrease of HCV RNA load was noticed, which raised the possibility of an immune reconstitution against the HCV-infected hepatocytes with cell lysis. Liver biopsy specimen demonstrated no evidence for autoimmune liver disease or fibrosis. Clinical evolution was favorable and serum transaminases returned to normal levels and HCV RNA load increased to baseline values following nivolumab cessation. The current case suggests an anti-HCV activity of anti-PD-1 treatment in the setting of concomitant HCV viremia and lung carcinoma.